Literature DB >> 24637708

Immunogenicity of Escherichia coli expressed envelope 2 protein of Chikungunya virus.

Nagesh K Tripathi1, Raj Priya2, Ambuj Shrivastava2.   

Abstract

Chikungunya fever, a re-emerging infection, is an arthropod-borne viral disease prevalent in different parts of the world, particularly Africa and South East Asia. Chikungunya virus envelope 2 protein is involved in binding to host receptors and it contains specific epitopes that elicit virus neutralizing antibodies. A highly immunogenic, recombinant Chikungunya virus envelope 2 protein was produced by bioreactor in Escherichia coli for development of a suitable diagnostic and vaccine candidate. This protein was refolded and further purified to achieve biologically active protein. The biological function of refolded and purified recombinant envelope 2 protein of Chikungunya virus was confirmed by its ability to generate envelope 2 specific antibodies with high titers in animal models. These findings suggest that recombinant envelope 2 protein of Chikungunya virus in combination with compatible adjuvant is highly immunogenic. Thus, recombinant envelope 2 protein can be a potential diagnostic reagent and vaccine candidate against Chikungunya virus infection.

Entities:  

Keywords:  Chikungunya; Escherichia coli; Plackett-Burman design; fermentation; immunogenicity; vaccine; virus

Mesh:

Substances:

Year:  2014        PMID: 24637708      PMCID: PMC4101013          DOI: 10.4161/bioe.28336

Source DB:  PubMed          Journal:  Bioengineered        ISSN: 2165-5979            Impact factor:   3.269


  13 in total

1.  Production of recombinant Chikungunya virus envelope 2 protein in Escherichia coli.

Authors:  Nagesh K Tripathi; Raj Priya; Ambuj Shrivastava
Journal:  Appl Microbiol Biotechnol       Date:  2013-12-13       Impact factor: 4.813

2.  Glucose-limited high cell density cultivations from small to pilot plant scale using an enzyme-controlled glucose delivery system.

Authors:  Julia Glazyrina; Mirja Krause; Stefan Junne; Florian Glauche; Dirk Storm; Dirk Strom; Peter Neubauer
Journal:  N Biotechnol       Date:  2011-11-09       Impact factor: 5.079

Review 3.  Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.

Authors:  Chung-Jr Huang; Henry Lin; Xiaoming Yang
Journal:  J Ind Microbiol Biotechnol       Date:  2012-01-18       Impact factor: 3.346

4.  A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.

Authors:  Wataru Akahata; Zhi-Yong Yang; Hanne Andersen; Siyang Sun; Heather A Holdaway; Wing-Pui Kong; Mark G Lewis; Stephen Higgs; Michael G Rossmann; Srinivas Rao; Gary J Nabel
Journal:  Nat Med       Date:  2010-01-28       Impact factor: 53.440

5.  Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.

Authors:  Manish Kumar; A B Sudeep; Vidya A Arankalle
Journal:  Vaccine       Date:  2012-08-08       Impact factor: 3.641

Review 6.  Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli.

Authors:  Amulya K Panda
Journal:  Adv Biochem Eng Biotechnol       Date:  2003       Impact factor: 2.635

7.  Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.

Authors:  Brian A Bell; James F Wood; Reeta Bansal; Hatem Ragab; John Cargo; Michael A Washington; Chloe L Wood; Lisa A Ware; Christian F Ockenhouse; Anjali Yadava
Journal:  Vaccine       Date:  2009-01-10       Impact factor: 3.641

8.  Development of a pilot-scale production process and characterization of a recombinant Japanese encephalitis virus envelope domain III protein expressed in Escherichia coli.

Authors:  Nagesh K Tripathi; Ambuj Shrivastava; Karttik C Biswal; P V Lakshmana Rao
Journal:  Appl Microbiol Biotechnol       Date:  2012-05-06       Impact factor: 4.813

9.  Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells.

Authors:  Stefan W Metz; Corinne Geertsema; Byron E Martina; Paulina Andrade; Jacco G Heldens; Monique M van Oers; Rob W Goldbach; Just M Vlak; Gorben P Pijlman
Journal:  Virol J       Date:  2011-07-15       Impact factor: 4.099

10.  Production of recombinant nonstructural 1 protein in Escherichia coli for early detection of Japanese encephalitis virus infection.

Authors:  Nagesh K Tripathi; Jyoti S Kumar; Karttik C Biswal; P V Lakshmana Rao
Journal:  Microb Biotechnol       Date:  2012-03-27       Impact factor: 5.813

View more
  2 in total

1.  Expression, Purification, and Refolding of Chikungunya Virus Full-Length Envelope E2 Protein along with B-Cell and T-Cell Epitope Analyses Using Immuno-Informatics Approaches.

Authors:  Manisha Shukla; Pankaj Chandley; Suman Tapryal; Narendra Kumar; Sulakshana P Mukherjee; Soma Rohatgi
Journal:  ACS Omega       Date:  2022-01-14

2.  Chikungunya E2 Protein Produced in E. coli and HEK293-T Cells-Comparison of Their Performances in ELISA.

Authors:  Flávia Fonseca Bagno; Lara Carvalho Godói; Maria Marta Figueiredo; Sarah Aparecida Rodrigues Sérgio; Thaís de Fátima Silva Moraes; Natália de Castro Salazar; Young Chan Kim; Arturo Reyes-Sandoval; Flávio Guimarães da Fonseca
Journal:  Viruses       Date:  2020-08-26       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.